We report a case of Erdheim-chester disease, a rare non-langerhans histiocytosis revealed by polydipsia-polyuria syndrome in a 26 years old woman, trated by interferon with a good response.
Introduction
Erdheim-Chester disease (ECD) is a rare, non-inherited, nonLangerhans form of histiocytosis of unknown origin. [1] First described in 1930 by William Chester as "lipoid granulomatose" [2] , ECD is characterized by tissue xanthomatous infiltration by spumous histiocytes. Immunohistochemical staining results are positive for CD68 and negative for CD1a, whereas those for S-100 protein may be negative or positive. [3] The treatment is essentially based on interferon alpha administration. We report in this paper, a typical ECD in a young woman revealed by polydipsia-polyuria syndrome secondary to a hypophyseal infiltration, with good response to treatment by interferon alpha. Some patients may present with pericarditis possibly leading to tamponade [1] . The prognosis of this histiocytosis is relatively poor, as reported in Veyssier-Belot et al review, 22 (59%) of 37 patients died in a mean follow up of 2.7 years. Common causes of death were cadiac failure and pulmonary fibrosis [5] . The first line treatment of ECD is based on interferon-α administration which improves survival in multisystemic disease, it should be prescribed at high dose if there is central nervous system and/or cardiovascular involvement [7] . Indeed, we have now treated our patient with interferon alpha for 12 months without serious complications.
Patient and observation
Although the clinical symptoms of our patient seem to be stable, the efficacy of interferon alpha has been reported to be limited especially in CNS and cardiovascular involvement [1, 7] . The optimal duration of interferon remains unknown. Other effective treatments have been reported being effective in some case reports or small series, such as steroids, biphosphonates, imatinib mesylate, Page number not for citation purposes 3 cladribine and autologous stem cell transplantation. Recently, it was found that BRAF V600E mutation is recurrent in this disease; about half of ECD patients carry this mutation [8] . Thus Vemurafenib, an inhibitor of mutant BRAF, might be an interesting effective treatment alternative of the ECD as reported recently in three multisystemic and refractory ECD patients [9] .
Conclusion
ECD is a very rare histiocytosis as about 450 cases have been reported till now. Its incidence might be underestimated due to lack of knowledge and difficulty of diagnosis. Although its prognosis remains poor, the recent discovery of the recurrent BRAF mutation and the spectacular response to BRAF targeted therapy might improve the outcome of ECD patients.
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